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Abstract Daptomycin is a lipopeptide antibiotic active
against gram-positive organisms and recently approved for
marketing in Japan. This study investigates the efﬁcacy and
safety of daptomycin in Japanese patients with skin and soft
tissue infections (SSTIs) caused by methicillin-resistant
Staphylococcus aureus (MRSA) for regulatory ﬁling in
Japan. Overall, 111 Japanese patients with SSTI were ran-
domized in this open-label, randomized, active-comparator
controlled, parallel-group, multicenter, phase III study.
Patients received intravenous daptomycin 4 mg/kg once
daily or vancomycin 1 g twice daily for 7–14 days. Efﬁcacy
was determined by a blinded Efﬁcacy Adjudication
Committee. Among patients with SSTIs caused by MRSA,
81.8 % (95 % CI, 69.1–90.9) of daptomycin recipients and
84.2 % (95 % CI, 60.4–96.6) of vancomycin recipients
achieved a successful clinical response at the test-of-cure
(TOC) visit. The microbiological success rate against
MRSA at the TOC visit was 56.4 % (95 % CI, 42.3–69.7)
with daptomycin and 47.4 % (95 % CI, 24.4–71.1) with
vancomycin. Daptomycin was generally well tolerated;
most adverse events were of mild to moderate severity.
The measurement of daptomycin concentration in plasma
revealed that patients with mild or moderate impaired renal
function showed similar pharmacokinetics proﬁles to
patients with normal renal function. Clinical and microbio-
logical responses, stratiﬁed by baseline MRSA susceptibil-
ity, suggested that patients infected with MRSA of higher
daptomycin MIC showed a trend of lower clinical success
with a P value of 0.052 by Cochran–Armitage test. Dapto-
mycin was clinically and microbiologically effective for the
treatment of MRSA-associated SSTIs in Japanese patients.
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Introduction
Daptomycin (CUBICIN) is a novel cyclic lipopeptide that
is derived from the fermentation of a strain of Streptomyces
roseosporus. In contrast to other antibacterial agents,
daptomycin targets multiple aspects of bacterial membrane
function. Upon oligomerization on a bacterial membrane,
daptomycin causes rapid depolarization, leading to a loss
of membrane potential that ultimately inhibits RNA,
DNA, and protein synthesis [1, 2]. Because of this novel
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mechanism of action, daptomycin is an appropriate option
for treating bacteria resistant to other antibacterial agents
[3, 4]. In vitro, daptomycin has demonstrated rapid, con-
centration-dependent bactericidal activity against many
clinically signiﬁcant gram-positive pathogens, including
methicillin-resistant Staphylococcus aureus (MRSA) [5–7].
In clinical trials, the efﬁcacy of daptomycin in the
treatment of complicated skin and soft tissue infections
(cSSTIs) caused by gram-positive bacteria was demon-
strated in an analysis of two comparative phase III studies
in a total of 1,092 patients [8]. In overseas studies, dapto-
mycin 4 mg/kg was not inferior to the active comparator
(vancomycin 1 g twice daily or a semisynthetic penicillin).
In the daptomycin group, only 28 cases were microbio-
logically evaluable as MRSA infections. Thus, the efﬁcacy
data on MRSA-associated infection were limited.
According to the results of a 25-year longitudinal study in
10,000 Japanese hospitalized patients with infectious
respiratory diseases, the proportion of Staphylococcus aur-
eus-related infections caused by MRSA strains increased
rapidly in 1986 and, between 1990 and 2005, MRSA
accounted for approximately 60 % of all S. aureus infec-
tions in this study [9]. In a separate study conducted between
2004 and 2008, 45.5 % of all S. aureus isolates detected in
inpatients were MRSA strains [10].
In Japan, daptomycin has been developed and approved
within the category of anti-MRSA drugs, although intra-
venous daptomycin is approved in more than 70 countries
for use against gram-positive bacteria susceptible to
daptomycin, including methicillin-susceptible S. aureus
(MSSA), Streptococcus pyogenes, Streptococcus agalactiae,
Streptococcus dysagalactiae subsp. equisimilis, and Enter-
ococcus faecalis (vancomycin-susceptible isolates only). A
single phase I study examining single and multiple doses of
daptomycin in Japanese subjects was previously conducted
in Japan [11]. No serious adverse events occurred in this
study.
We conducted a phase III study in SSTI and bacteremia
patients for the purpose of regulatory ﬁling in Japan. In this
report, as a part of the registry study, the safety and efﬁcacy
of daptomycin in Japanese patients with MRSA-associated
SSTIs are reported by comparing them to those of vanco-
mycin. The pharmacokinetics of daptomycin in Japanese
patients and susceptibilities of the isolated pathogens are
also reported.
Patients and methods
Study design, patients, and treatment
This is a randomized, open-label, active-comparator
controlled, parallel-group, multicenter, phase III study
conducted across 61 Japanese medical institutions between
2008 and 2010. Male and female patients aged C20 years
who required hospitalization and treatment with systemic
antibacterial agents and gave consent to participate in the
study were included. Inclusion criteria were (1) isolation of
MRSA from specimens obtained within 3 days before
starting treatment or the detection of gram-positive cocci
and a strong suspicion of MRSA infection; and (2) pres-
ence of at least three of the following: drainage/exudate,
erythema, ﬂuctuance, localized warmth, pain/tenderness,
swelling/induration, temperature[37.5 C (oral) or 37 C
(armpit), out-of-normal-range WBC count, stab-cell[15 %,
pulse rate[90/min, respiratory rate[20/min, positive CRP
(C-reactive protein). Patients were excluded from the study
for any of the following reasons: previous systemic anti-
microbial therapy for [24 h during the previous 3 days
(unless unresponsive to C72 h antibiotic therapy or
detection of a resistant pathogen); presence of osteomy-
elitis, infectious arthritis, pneumonia (known or suspected),
or human immunodeﬁciency virus (HIV) infection; pres-
ence or potential for developing severe neutropenia
(neutrophils\500/ll); shock, uncontrollable hypotension;
oliguria, undergoing hemodialysis or peritoneal dialysis;
blood creatine phosphokinase (CPK) level C2 9 the upper
limit of normal (ULN); creatinine clearance\30 ml/min;
aspartate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) C5 9 the ULN; total bilirubin C3.0 mg/dl.
Patients with perirectal abscess, myositis, concomitant
gangrene requiring debridement, multiple infected ulcers,
or third-degree burns covering[10 % of the body surface
area; septicemia; only surgery and/or drainage required to
cure infection; or allergy or contraindications to vanco-
mycin were also excluded.
Patients were randomized 4:1 to receive intravenous
daptomycin (4 mg/kg over 30 min) once daily or vanco-
mycin (1 g over at least 60 min) twice daily for 7–14 days.
During therapeutic drug monitoring, the doses of vanco-
mycin were adjusted based on age, renal function, and drug
concentrations during therapeutic drug monitoring based
on the discretion of investigators, and the trough concen-
trations were not recorded.
Assessments
Clinical and microbiological response at test-of-cure
(TOC) was used as the primary endpoint for efﬁcacy
evaluation in this study.
Clinical responses at TOC were evaluated by study
investigators within 7–14 days of the last dose of study
medication and conﬁrmed by the Efﬁcacy Adjudication
Committee (EAC), which was composed of ﬁve medical
experts blinded to study therapy. By deﬁnition, a successful
clinical response had to meet all the following criteria: an
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EAC-conﬁrmed clinical response of ‘‘cured’’ (resolution of
clinically signiﬁcant signs and symptoms) or ‘‘improved’’
(partial resolution of clinically signiﬁcant signs and
symptoms) at both end-of-treatment (EOT) and TOC; the
patient did not receive a non-study antibacterial agent that
could potentially have been effective against the causative
pathogen; 4 days or more of study drug administration to
the patient.
Microbiological responses at TOC were conﬁrmed by
the EAC and were based on culture results for causative
gram-positive cocci isolated at baseline. A successful
microbiological response was deﬁned as ‘‘eradication of
pathogen’’ (admission pathogen absent in culture) or
‘‘presumed eradication of the pathogen’’ (no material
available for culture but patient was deemed as cured or
improved by the study investigator).
The primary efﬁcacy analysis was conducted in the
modiﬁed intent-to-treat (MITT)-MRSA population, which
included all patients who received at least one dose of
study drug and in whom MRSA infection was conﬁrmed on
screening cultures. The microbiological efﬁcacy in patients
with gram-positive infections other than MRSA was also
assessed in an exploratory manner. The clinical and
microbiological success rates were calculated by treatment
group for the primary efﬁcacy endpoints, and 95 % conﬁ-
dence intervals were calculated using the Clopper–Pearson
method. Safety analyses were conducted in the all-patients-
as-treated population, which consisted of all randomized
patients who received at least one dose of the study treat-
ment. Safety parameters included adverse experiences as
assessed by investigators, laboratory tests, and vital signs.
CPK was set as one of the important safety parameters
because CPK elevation was observed in dog toxicology
studies and in the early period of clinical development
when daptomycin was frequently administered. CPK
[500 U/l was deﬁned as predeﬁned limits of change.
Minimum inhibitory concentration (MICs) of baseline
MRSA isolates were measured manually by the broth
microdilution method according to the CLSI testing
guidelines (M7-A7, 2006) at Mitsubishi Chemical Medi-
ence Corporation, Tokyo, Japan. Daptomycin was provided
from Cubist Pharmaceuticals, and the frozen panel
including daptomycin, vancomycin, linezolid, teicoplanin,
arbekacin, and oxacillin was prepared by Eiken Chemical
Co. The relationship between clinical response and in vitro
susceptibility was investigated by Cochran–Armitage test
in an exploratory manner.
Pharmacokinetics analysis
Blood samples for determining daptomycin plasma con-
centration were obtained at screening, day 4 pre-infusion,
the end-of-infusion, 30 min to 2 h post-dose, 4–10 h post-
dose, and day 5 pre-infusion. The plasma concentration of
daptomycin was measured by reverse-phase high perfor-
mance liquid chromatography (HPLC) (Waters WISP 717
plus), and pharmacokinetics were calculated using a pop-
ulation pharmacokinetic method based on 18 non-Japanese
studies (10 phase I studies and 8 phase II/III studies) and
2 Japanese studies (1 phase I study and the present
study). The population PK proﬁles in patients with gram-
positive infections (cSSSI) were determined using a two-
compartment model with linear elimination characteristics.
T1/2, CL/wt, AUC0–24 h, and Cmax were calculated and are
shown after stratiﬁcation for renal function (CLcr) at
baseline.
Results
Patient disposition
Of the 111 patients who were randomized, 88 received
daptomycin and 22 received vancomycin. The baseline
characteristics of the population as treated are presented in
Table 1. Age, gender, body weight, creatinine clearance,
and prior use of antibiotics were similar between the
treatment groups. The doses of vancomycin were main-
tained in 17 patients, but increased in 3 patients and
decreased in 2 patients based on the therapeutic drug
monitoring results of the treatment period. A total of 110
patients with SSTIs received at least one dose of the study
drug and were included in the safety population. Thirty-six
(36) patients with no MRSA identiﬁed as causative path-
ogen (33 patients receiving daptomycin 4 mg/kg and 3
patients receiving vancomycin) were excluded from the
efﬁcacy analysis of MITT-MRSA population.
Efﬁcacy evaluation
The rates of clinical and microbiological success for
MITT-MRSA population are shown in Table 2. Because
the patients were randomized regardless of the causative
pathogen, the number of patients in MITT-MRSA resulted
in a ratio of approximately 3:1 for daptomycin and van-
comycin. Clinical success was achieved by 81.8 % (45/55
patients; 95 % CI, 69.1–90.9) of daptomycin recipients and
84.2 % (16/19; 95 % CI, 60.4–96.6) of vancomycin
recipients. In patients with wound or burn, which were the
most common causes, 81.6 % (31/38 patients) of dapto-
mycin recipients and 84.6 % (11/13) of vancomycin
recipients achieved clinical success. The rate of microbi-
ological success against MRSA was 56.4 % (31/55
patients; 95 % CI, 42.3–69.7) in daptomycin recipients and
47.4 % (9/19; 95 % CI, 24.4–71.1) in vancomycin recipi-
ents. Daptomycin was also effective against a number of
J Infect Chemother (2013) 19:447–455 449
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other gram-positive cocci including MSSA and E. faecalis
that were shown to be the cause of infection at baseline
(Table 3).
Safety evaluation
Adverse events occurred in 70.5 and 86.4 % of patients
treated with daptomycin and vancomycin, respectively
(Table 4). Events considered to be related to the study drug
occurred in 21.6 % (daptomycin) and 27.3 % (vancomy-
cin) of patients, and six and four serious adverse events
occurred in daptomycin recipients and vancomycin recip-
ients, respectively. A drug-related serious adverse event
(anaphylactic shock) occurred in one patient treated with
daptomycin; this event occurred just after the initial dosing
and resolved 4 days after drug treatment discontinuation.
Table 1 Baseline demographic
of all patients
qd once daily, bid twice daily,
CLcr creatinine clearance,
MRSA methicillin-resistant
Staphylococcus aureus
a Unless otherwise speciﬁed,
values are expressed as n (%)
b Anti-MRSA agent used
within 28 days before the start
of study drug administration
Baseline characteristica Daptomycin 4 mg/kg
qd (n = 88)
Vancomycin 1 g bid
(n = 22)
Age (years), median (range) 69.0 (22–92) 70.0 (29–82)
Gender (male) 47 (53.4) 15 (68.2)
Bodyweight (kg), median (range) 54.00 (28.3–117.8) 52.25 (36.5–78.3)
CLcr (ml/min), median (range) 78.14 (23.1–260.8) 78.17 (37.7–153.7)
\30 1 (1.1) 0 (0.0)
C30 to\50 17 (19.3) 5 (22.7)
C50 to\80 28 (31.8) 7 (31.8)
C80 41 (46.6) 10 (45.5)
Prior anti-MRSA antibioticsb 10 (11.4) 2 (9.1)
Table 2 EAC-assessed clinical and microbiological success rate for MITT-MRSA at TOC
Analysis group and disease type Daptomycin 4 mg/kg qd Vancomycin 1 g bid
n/Na Success % (95 % CIb) n/Na Success % (95 % CIb) P valueg
Clinical success
MITT-MRSA 45/55 81.8 (69.1–90.9) 16/19 84.2 (60.4–96.6) 0.593
Deep skin infectionc 4/6 66.7 0/0 0.0 –
Wound or burnd 31/38 81.6 11/13 84.6 0.597
Erosion or ulcere 9/9 100.0 4/5 80.0 0.090
Other infectionf 1/2 50.0 1/1 100.0 0.760
Microbiological success
MITT-MRSA 31/55 56.4 (42.3–69.7) 9/19 47.4 (24.4–71.1) 0.250
Deep skin infectionc 4/6 66.7 0/0 0.0 –
Wound or burnd 23/38 60.5 7/13 53.8 0.338
Erosion or ulcere 4/9 44.4 2/5 40.0 0.438
Other infectionf 0/2 0.0 0/1 0.0 0.500
qd once daily, bid twice daily, EAC Efﬁcacy Adjudication Committee, MITT modiﬁed intent-to-treat, MRSA methicillin-resistant Staphylococcus
aureus, TOC test-of-cure
a n/N number of patients with an EAC-assessed clinical or microbiological success/number of patients in the analysis population
b Calculated using the Clopper–Pearson method
c Including cellulitis and abscess-related disease
d Including secondary infections of wounds, surgical wounds, burns, and gastric ﬁstulas
e Including secondary infections of diabetic and nondiabetic ulcers and decubitus
f Including impetigo contagiosa, pyoderma, and genital psoriasis
g P value is based on Miettinen and Nurminen methods
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Elevation of ALT and AST was the most common
adverse event in both daptomycin and vancomycin groups.
CPK [500 U/l was found in one daptomycin recipient
(maximum level, 2,545 U/l) and in one vancomycin reci-
pient (maximum level, 592 U/l). These CPK elevations
were not associated with clinical symptoms, and they
resolved within 6 days after the last dose in the daptomycin
recipient. In addition, 9.1 % of daptomycin recipients and
9.1 % of vancomycin recipients had CPK levels[200 U/l.
Furthermore, none of the CPK elevations in this study led
to study discontinuation or was serious. Overall, three
patients with SSTIs died (one in daptomycin group; two in
Table 3 Microbiological
success by causative pathogens
other than MRSA
n/N number of microbiological
successes/number of patients
with causative pathogen
Causative pathogen n/N (%)
Daptomycin 4 mg/kg qd Vancomycin 1 g bid
Methicillin-susceptible Staphylococcus aureus 10/16 (62.5) 1/2 (50.0)
Enterococcus faecalis 7/10 (70.0) 0/0 (0.0)
Streptococcus equisimilis 0/3 (0.0) 0/0 (0.0)
Streptococcus agalactiae 0/1 (0.0) 1/1 (100.0)
Streptococcus pyogenes 1/1 (100.0) 1/1 (100.0)
Enterococcus faecium 0/1 (0.0) 1/1 (100.0)
Coagulase-negative Staphylococcus 1/1 (100.0) 0/0 (0.0)
Staphylococcus haemolyticus 1/1 (100.0) 0/0 (0.0)
Staphylococcus schleiferi 0/1 (0.0) 0/0 (0.0)
a-Hemolytic Streptococcus 0/1 (0.0) 0/0 (0.0)
c-Hemolytic Streptococcus 1/1 (100.0) 0/0 (0.0)
Enterococcus gallinarum 0/1 (0.0) 0/0 (0.0)
Peptostreptococcus anaerobius 1/1 (100.0) 0/0 (0.0)
Peptostreptococcus magnus 0/1 (0.0) 0/0 (0.0)
Table 4 Summary of all adverse events and speciﬁc adverse events occurring with a frequency[5 % among patients treated with daptomycin or
vancomycin
Daptomycin 4 mg/kg qd
(N = 88)
Vancomycin 1 g bid
(N = 22)
P valuea
n (%) n (%)
Summary
Any adverse event 62 (70.5) 19 (86.4) 0.934
Clinical event 51 (58.0) 17 (77.3) 0.952
Laboratory event 26 (29.5) 7 (31.8) 0.582
Drug-related adverse event 19 (21.6) 6 (27.3) 0.714
Clinical event 9 (10.2) 4 (18.2) 0.848
Laboratory event 13 (14.8) 4 (18.2) 0.653
Serious adverse event 6 (6.8) 4 (18.2) 0.951
Drug-related serious adverse event 1 (1.1) 0 (0.0) 0.309
Clinical adverse events ([5 % in either daptomycin- or vancomycin-treated patients)
Pruritus 2 (2.3) 2 (9.1) 0.936
Erythema 0 (0.0) 2 (9.1) 0.998
Pyrexia 6 (6.8) 2 (9.1) 0.643
Diarrhea 2 (2.3) 2 (9.1) 0.936
Laboratory adverse events ([5 % in either daptomycin- or vancomycin-treated patients)
AST increased 9 (10.2) 3 (13.6) 0.676
ALT increased 9 (10.2) 3 (13.6) 0.676
C-reactive protein increased 4 (4.5) 2 (9.1) 0.798
ALT alanine aminotransferase, AST aspartate aminotransferase, n number of patients experiencing an event
a P value is based on Miettinen and Nurminen methods
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vancomycin group), but none of the deaths was considered
drug related.
Pharmacokinetic evaluation with various renal
functions
Pharmacokinetic parameters according to renal function
are shown in Table 5. Following the administration of
daptomycin 4 mg/kg once daily, the mean CL/wt values in
patients with mild (CLcr, 50–80 ml/min), moderate (CLcr,
30 to\50 ml/min), and severe (CLcr,\30 ml/min) renal
impairment were approximately 15, 15, and 38 % lower,
respectively, than those in patients with normal renal
function (CLcr,[80 ml/min). The mean steady-state sys-
temic exposure (AUC), and t1/2, for daptomycin increased
with decreasing renal function, although the mean AUC
was not markedly different for patients with CLcr
30–80 ml/min compared with those with normal renal
function. The AUC for one patient with CLcr\30 ml/min
was approximately 1.4 times higher than that in patients
with normal renal function.
Susceptibility of MRSA isolates
Susceptibility of all the MRSA isolates at screening was
measured. The daptomycin minimum inhibitory concen-
tration (MIC) value of all 74 baseline MRSA isolates was
below the CLSI and US FDA breakpoint of susceptibility
of B1 lg/ml. The MIC90 (MIC range) for daptomycin,
vancomycin, linezolid, teicoplanin, arbecacin, and oxacil-
lin were 0.5 (0.25–1), 1 (0.5–2), 2 (1–4), 4 (0.25–8), 2
(0.25–4), and[128 (16 to[128) lg/ml, respectively.
Clinical and microbiological responses at TOC stratiﬁed
by baseline MRSA susceptibility are shown in Table 6.
Patients infected with MRSA of higher-MIC daptomycin
showed a trend of lower clinical success with a P value of
0.052 by Cochran–Armitage test. The trend analysis per
each type of infection was also tested. The response rate in
wound or burn showed numerically similar trends (MIC
0.25, 0.5, and 1 showed clinical response of 87.5, 82.4, and
50.0 %, respectively). However, that was not statistically
signiﬁcant (P = 0.343), probably because of the limited
number of samples (n = 38). The trend of microbiological
success over each MIC was not clear (P = 0.846).
Discussion
This study was conducted to investigate the efﬁcacy, tol-
erability, and pharmacokinetics of daptomycin in Japanese
patients with SSTIs and bacteremia caused by MRSA.
Because the bacteremia arm was designed as a noncom-
parative study and the number of patients was very limited
(four patients as MITT-MRSA), only the results in SSTI
patients are shown in this report. In addition to daptomycin,
four anti-MRSA drugs (vancomycin, linezolid, teicoplanin,
and arbekacin) are available in Japan. Glycopeptides
(vancomycin and teicoplanin) and aminoglycosides (arbek-
acin) are known to cause renal toxicity, and these drugs are
administered with the provision that their plasma concen-
trations are monitored [12]. Linezolid, an oxazolidinone, is
known to cause myelosuppression, and its usage is essen-
tially limited to 28 days in Japan [13]. Daptomycin is
expected to add another choice to the treatment of MRSA
infections in Japanese patients without the safety limita-
tions of these other drugs. Thus, it is important to conﬁrm
the safety proﬁle of daptomycin, including CPK elevations,
exposure levels with regard to renal function, and its efﬁ-
cacy against MRSA infections in Japanese patients.
Because this study was conducted in support of the new
drug application of daptomycin in Japan, it was important to
collect as many patients who had received daptomycin as
possible. Thus, patients were randomized to daptomycin in
much higher proportion than to vancomycin. As this was
Table 5 Population pharmacokinetic parameters for daptomycin 4 mg/kg at steady state according to baseline renal function
Renal function status t1/2 (h) CL/wt (ml/h/kg) AUC0–24 h (lg h/ml) Cmax (lg/ml)
Normal (CLcr[80 ml/min)
N = 38
9.31 ± 1.77 13.6 ± 6.7 337 ± 115 45.5 ± 12.1
Mild impairment (CLcr 50 to 80 ml/min)
N = 28
11.80 ± 2.79 11.5 ± 4.3 400 ± 136 46.0 ± 12.5
Moderate impairment (CLcr 30 to\50 ml/min)
N = 15
14.58 ± 3.52 11.6 ± 6.5 414 ± 163 39.5 ± 14.2
Severe impairment (CLcr\30 ml/min)
N = 1
16.20 8.5 470 52.3
Values are mean ± SD
CLcr creatinine clearance estimated using the Cockcroft–Gault equation with actual body weight, CL/wt total clearance from plasma adjusted for
body weight, AUC0–24 h area under the plasma concentration–time curve from time 0 to 24 h, Cmax maximum plasma concentration
452 J Infect Chemother (2013) 19:447–455
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further compounded by the limited sample size, there was no
statistical power to compare the efﬁcacy of the two groups. It
should also be noted that the proportion of infection types in
each treatment group was not the same in ‘‘Deep skin
infection’’ (no patient in vancomycin group) and ‘‘Erosion or
ulcer’’ (higher proportion in vancomycin group than in
daptomycin group). However, as the majority had ‘‘Wound
or burn,’’ which was found in similar proportions in the two
treatment groups (69.1 % for the daptomycin group and
68.4 % for the vancomycin group), the imbalance in ‘‘Deep
skin infection’’ and ‘‘Erosion or ulcer’’ was considered to
have a limited impact on the total efﬁcacy results.
In patients with SSTIs, the primary efﬁcacy endpoint,
namely, the clinical and microbiological response at TOC in
the MITT-MRSA population, was similar between the dap-
tomycin and vancomycin groups, and was also similar to
those observed in previously published phase III trials con-
ducted in other countries [8], indicating that daptomycin is
effective for the treatment of SSTIs in Japanese patients. In
the present study, daptomycin was also found to be effective
in treating SSTIs caused by MSSA and E. faecalis, which is
consistent with reports from previous studies [8].
Daptomycin at a dose of 4 mg/kg once daily was gen-
erally well tolerated. There were no drug-related deaths. A
drug-related serious adverse event (anaphylactic shock)
was reported in one patient treated with daptomycin 4 mg/
kg, and this event resolved after discontinuing therapy.
Similar to other antibiotics, daptomycin should be used
with care in patients with hypersensitivities. Elevated CPK
levels have been reported in some daptomycin studies [8,
14–16]. In the present study, the daptomycin and vanco-
mycin groups had each one patient whose CPK increased to
[500 U/l, but the levels for both patients subsequently
returned to the normal range, and no associated muscular
symptoms were observed. These safety data show that the
overall safety proﬁle of daptomycin in Japanese patients
was similar to the known proﬁles reported in prior studies.
Daptomycin is eliminated primarily by the kidneys, and
the baseline CLcr value in patients is known to be related to
the plasma level of daptomycin. The mean AUC was
not markedly different in patients with mild or moderate
renal impairment compared with patients with normal
renal function. However, the AUC for one patient with
CLcr\30 ml/min was approximately 1.4 times higher than
that for patients with normal renal function. This ﬁnding
supports the current label, recommending dose modiﬁca-
tions in such patients, including its administration every
48 h.
Of all the antibacterial agents tested for susceptibility
against the MRSA isolates detected at screening, dapto-
mycin showed potent antibacterial activity, with a MIC90
of 0.5 lg/ml. The susceptibility of MRSA isolates in Japan
seems similar to that reported elsewhere [6, 7, 17]. Patients
with baseline pathogens with a higher MIC tended to show
less favorable clinical responses to daptomycin. These data
suggest that assessment of pathogen susceptibility can help
clinicians select the most appropriate treatment.
In addition to 4 mg/kg daptomycin for the treatment of
SSTI, 6 mg/kg daptomycin is indicated for the treatment of
bacteremia and infectious endocarditis in Japan and other
countries. Furthermore, the safety and efﬁcacy of higher
doses of daptomycin (8–12 mg/kg) were clinically inves-
tigated in Europe and the United States [16, 18]. Some
guidelines on the treatment of MRSA infection also indi-
cate the use of 8–10 mg/kg for the treatment of bacteremia
and endocarditis, as recommended by some experts [19,
20]. Because the safety proﬁle in Japanese healthy subjects
who received single doses of 2–12 mg/kg and multiple
doses of 4–10 mg/kg daptomycin was reported as generally
safe [11], it may be interesting to investigate the efﬁcacy of
higher doses of daptomycin in Japanese patients having
complicated diseases or less susceptible strains against
vancomycin (e.g., MIC[2 lg/ml).
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